TABLE 2.
Summary of baseline characteristics of the study participants included in the individual participant data meta-analysis
| Demographic | All (n = 326) | Exercise (n = 191) | Control (n = 135) |
| Agea | 48.58, 16.33, 18/80 | 48.2, 16.4, 18/78 | 49.1, 16.3, 18/80 |
| Maleb | 205 | 120 (59%) | 85 (41%) |
| BMI meana | 28.31, 5.73,18.23/58.06 | 28.4, 5.25, 18.9/51 | 28.1, 6.37, 18.2/58.1 |
| Hypertensionb | 109 | 63 (58%) | 46 (42%) |
| Blood pressure | |||
| Systolic (mmHg)a | 129.54, 15.18, 90.5/188 | 130., 14.7, 95/188 | 128., 15.8, 90.5/167 |
| Diastolic (mmHg)a | 76.19, 10.12, 45/105 | 77.0, 9.52, 54.3/105 | 75.1, 10.9, 45/99 |
| Mean arterial (mmHg)a | 94.31, 10.50, 62.22/131 | 95.1, 9.77, 71.7/131 | 93.2, 11.4, 62.2/119 |
| Medicationsc | |||
| Angiotensin-converting enzyme inhibitor | 58 | 33 (57%) | 25 (43%) |
| Beta blocker | 33 | 21 (64%) | 12 (36%) |
| Calcium channel blocker | 37 | 22 (59%) | 15 (41%) |
| Diuretic | 61 | 39 (64%) | 22 (36%) |
| arb ii antagonist | 67 | 38 (57%) | 29 (43%) |
aReporting mean, SD, min/max.
bReporting totals and percentages for the exercise and control groups.
cReporting totals and percentages for the exercise and control groups without Gordon et al. [45], as the data do not show type of medication for this study.